Transgene Financials

TRGNF Stock  USD 1.59  0.00  0.00%   
We advise to exercise analysis of Transgene fundamentals to see if markets are presently mispricing the firm. We were able to interpolate thirty-two available drivers for Transgene SA, which can be compared to its competition. The stock experiences a normal downward fluctuation but is a risky buy. Check odds of Transgene to be traded at $1.5741 in 90 days.
  

Transgene Stock Summary

Transgene competes with Starbucks, Summit Hotel, Teleflex Incorporated, Arcos Dorados, and Avadel Pharmaceuticals. Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.
InstrumentUSA Pink Sheet View All
ExchangePINK Exchange
Business Address400, Boulevard Gonthier
SectorHealthcare
IndustryBiotechnology
BenchmarkDow Jones Industrial
Websitewww.transgene.fr
Phone33 3 88 27 91 00
CurrencyUSD - US Dollar

Transgene Key Financial Ratios

There are many critical financial ratios that Transgene's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Transgene SA reports annually and quarterly.

Transgene Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Transgene's current stock value. Our valuation model uses many indicators to compare Transgene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Transgene competition to find correlations between indicators driving Transgene's intrinsic value. More Info.
Transgene SA is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Transgene's earnings, one of the primary drivers of an investment's value.

Transgene SA Systematic Risk

Transgene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Transgene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Transgene SA correlated with the market. If Beta is less than 0 Transgene generally moves in the opposite direction as compared to the market. If Transgene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Transgene SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Transgene is generally in the same direction as the market. If Beta > 1 Transgene moves generally in the same direction as, but more than the movement of the benchmark.

Complementary Tools for Transgene Pink Sheet analysis

When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance